IL-15 Protein (His tag)

Catalog No. ABIN7121480

This Recombinant IL-15 protein is produced in HEK-293 Cells.

Quick Overview for IL-15 Protein (His tag) (ABIN7121480)

Target: IL-15 (IL15) (Interleukin 15 (IL15))

Protein Type: Recombinant

Origin: Rhesus Monkey, Cynomolgus

Source: HEK-293 Cells

Purity: >95 % as determined by SDS-PAGE.

Product Details

Purification tag / Conjugate: This IL-15 protein is labelled with His tag.

Purpose: Cynomolgus / Rhesus macaque IL-15 Protein, His Tag

Sequence: Asn 49 - Ser 162

Characteristics: Cynomolgus / Rhesus macaque IL-15, His Tag (IL5-C52H4) is expressed from human 293 cells (HEK293). It contains AA Asn 49 - Ser 162 (Accession # P48092-1).

Endotoxin Level: Less than 1.0 EU per μg by the LAL method.

Application Details

Application Notes: This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 14.9 kDa. The protein migrates as 14 kDa and 16-18 kDa under reducing (R) condition due to glycosylation.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: PBS, pH 7.4

Storage: -20 °C

Storage Comment: -20°C

Target Details

Target: IL-15 (IL15) (Interleukin 15 (IL15))

Alternative Name: IL-15

Background: Synonyms: IL-15,Interleukin-15,MGC9721,
Description: Interleukin 15 is also known as IL15, IL-15, and is a cytokine with structural similarity to IL-2. Like IL-2, IL-15 binds to and signals through the IL-2/IL-15 beta chain (CD122) and the common gamma chain (gamma-C, CD132). IL-15 is secreted by mononuclear phagocytes (and some other cells) following infection by virus(es). This cytokine induces cell proliferation of natural killer cells, cells of the innate immune system whose principal role is to kill virally infected cells. Interleukin 15 (IL-15) regulates T and natural killer (NK) cell activation and proliferation. Survival signals that maintain memory T cells in the absence of antigen are provided by IL-15. This cytokine is also implicated in NK cell development. In rodent lymphocytes, IL-15 prevents apoptosis by inducing an apoptosis inhibitor, BCL2L1/BCL-x(L). IL-15 has been shown to enhance the anti-tumor immunity of CD8+ T cells in pre-clinical models. A phase I clinical trial to evaluate the safety, dosing, and anti-tumor efficacy of IL-15 in patients with metastatic melanoma and renal cell carcinoma (kidney cancer) has begun to enroll patients at the National Institutes of Health.

Molecular Weight: 14.9 kDa

NCBI Accession: NP_001038196

Pathways: JAK-STAT Signaling, Glycosaminoglycan Metabolic Process